Indication: Prostate Cancer
A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-resistant Prostate Cancer and DNA-Repair Anomalies
Sub-indication: GU 16-37 Metastatic Castration-resistant prostate cancer
Line of Therapy: 1 previous line of taxane based chemo. 1 previous AR targeted therapy. No prior platinum therapy.
Principal Investigator: Joseph Maly, M.D.Norton Cancer Institute
Sponsor: Janssen Research & Development
Email for more information: GU-NCIResearch@nortonhealthcare.org